GSK2033

GSK2033

Biochem/physiol Actions

GSK2033 has the ability to repress gluconeogenic gene expression stimulated by GC (glucocorticoids), without altering immune-responsive GR (GC receptor) target genes. It helps to target several nuclear receptors that can alter hepatic gene expression.

GSK2033 is an antagonist of the nuclear receptor liver-X-receptor (LXR) with pIC50 values of 7.0 for LXRα and 7.4 for LXRβ. Treatment of murine CD41 T cells with GSK2033 enhanced cellular proliferation and Th1/Th2/Th17 differentiation. In another study, the conjugated linoleic acid (CLA)-induced expression of efflux protein ATP-binding-cassette transporter A1 (ABCA1) was completely abolished by preincubation with GSK2033, showing that CLA mediated regulation of ABCA-1 expression is LXR dependent.

Packaging

5, 25 mg in glass bottle

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour Quality Level InChI key InChI Manufacturer Storage Temp. Solubility Form Assay Price Quantity
3575165 GSK2033 white to beige 100 PSOXOVKYGWBTPB-UHFFFAOYSA-N 1S/C29H28F3NO5S2/c1-19-14-20(2)28(21(3)15-19)40(36,37)33(18-25-12-13-27(38-25)29(30,31)32)17-22-8-10-23(11-9-22)24-6-5-7-26(16-24)39(4,34)35/h5-16H,17-18H2,1-4
£757.71 (exc VAT) per 25MG
-
+
3575166 GSK2033 white to beige 100 PSOXOVKYGWBTPB-UHFFFAOYSA-N 1S/C29H28F3NO5S2/c1-19-14-20(2)28(21(3)15-19)40(36,37)33(18-25-12-13-27(38-25)29(30,31)32)17-22-8-10-23(11-9-22)24-6-5-7-26(16-24)39(4,34)35/h5-16H,17-18H2,1-4
£188.04 (exc VAT) per 5MG
-
+